May 8, 2021
Business News

Releviate Therapeutics Appoints Jennifer Maynard to Its Scientific Advisory Board


SAN DIEGO–()–Releviate™ Therapeutics, a bio-pharmaceutical company addressing the needs of patients suffering from neuropathic pain, today welcomes Jennifer Maynard to its scientific advisory board. Maynard, who holds a doctorate in chemical engineering, bears deep expertise in engineering and development of antibody therapeutics. As a member of the board, she will provide strategic guidance for Releviate Therapeutics’ scientific research and technology development.

“Jennifer is recognized as one of the country’s leading antibody specialists for pharmaceutical companies,” said Sergey Sikora, CEO of Releviate Therapeutics. “Her experience with drug development is second to none. She has a proven track…



Click here to view the original article.

Related Posts

You might also like ...

Article feature image
CDC may roll out seasonal Covid-19 boosters to protect against variants – CNN
Article feature image
Copper Just Smashed Past a Record. Here’s What You Need to Know
AON Splash Image
Copper Just Smashed Past a Record. Here’s What You Need to Know – Bloomberg